The developer of protein-based drugs for the treatment of human diseases went public in February, raising $120 million by offering 10 million shares at $12 each. Shares close dtrading on Friady at $12.16 apiece.
The project passed muster with the City's design review board last week but the director of the City's Department of Design, Construction and Land Use has issued a "determination of significance" on the project relating to traffic impacts. The decision means an environmental impact statement will be required.
Zymogenetics also needs to obtain a shoreline permit ands approval from the landmarks commission--because two possibly historic single family homes are slated for demolition--before the Master Use Permit can be issued.
Written comments with regard to the director's decision are being accepted until April 24. They should be mailed to: Department of Design, Construction and Land Use; Attn: Michael Jenkins, Land Use Planner, 700 5th Avenue, Suite 2000; Seattle, Washington 98104-5070.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
